A partnership between CHOC and Masimo has developed technology to noninvasively monitor blood oxygen and hemoglobin levels in newborns.
Dr. John Cleary
CHOC has ordered cutting-edge tests of rapid whole-genome sequencing (rWGS) on 150 patients, with 76 of them getting a precise diagnosis.
A recently completed pilot program at CHOC and other California clinical sites helped target a baby’s specific genetic disease in just days.
To help address the needs of neonates and their families, CHOC will again host “NeoHeart: Cardiovascular Management of the Neonate.”